Description
Retatrutide is an investigational triple-hormone receptor agonist (GLP-1, GIP, and glucagon) being evaluated for weight management and type 2 diabetes. A single vial or dose of 40 mg is not an approved medical or clinical trial dosage; in Phase 3 clinical studies, weekly target doses range up to a maximum of 12 mg
Reviews
There are no reviews yet.